The agreement includes an option to extend the license on a global basis.

HCV genotyping is a guideline-supported test performed in combination with HCV screening and viral load testing, and laboratories in the US currently have limited technology options to address their molecular testing needs in this area.

GenMark Diagnostics chairman and CEO Chris Gleeson said that they are pleased for the licensing agreement with Innogenetics for the rights to its HCV genotyping patent estate.

“We believe that this license will allow us to enter a market that is ideally suited to our technology and will increase the value of the XT-8 system for our customers,” Gleeson said.

“The addition of HCV genotyping to our test menu will likely accelerate GenMark’s expansion into the largest molecular diagnostics laboratories in the US.”

Innogenetics CEO Christiaan De Wilde said that they are pleased to have completed this licensing agreement with GenMark Diagnostics and the combination of our global HCV genotyping patent estate with GenMark’s technology platform will provide additional testing options for physicians and patients.